Publications in collaboration with researchers from Institut d'Investigacions Biomèdiques August Pi i Sunyer (24)

2023

  1. Phase II Trial Evaluating Olaparib Maintenance in Patients with Metastatic Castration-Resistant Prostate Cancer Responsive or Stabilized on Docetaxel Treatment: SOGUG-IMANOL Study

    Cancers, Vol. 15, Núm. 21

  2. Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer

    Lung Cancer, Vol. 178, pp. 116-122

2022

  1. Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations

    European Journal of Cancer

  2. Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations

    European Journal of Cancer, Vol. 167, pp. 142-148

  3. Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study

    European Journal of Cancer, Vol. 168, pp. 12-24

  4. Type does matter. Use VIRGIN olive oil as your preferred fat to reduce your risk of breast cancer: case-control EpiGEICAM study

    European Journal of Clinical Nutrition, Vol. 76, Núm. 9, pp. 1343-1346

2021

  1. Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial

    The Lancet Oncology, Vol. 22, Núm. 6, pp. 858-871

  2. Epithelial-to-mesenchymal transition mediates resistance to maintenance therapy with vinflunine in advanced urothelial cell carcinoma

    Cancers, Vol. 13, Núm. 24

  3. Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer

    npj Precision Oncology, Vol. 5, Núm. 1

  4. Lung Cancer in Spain

    Journal of Thoracic Oncology

  5. Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial

    npj Breast Cancer, Vol. 7, Núm. 1

  6. Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial

    European Journal of Cancer, Vol. 148, pp. 382-394

  7. Trajectories of alcohol consumption during life and the risk of developing breast cancer

    British Journal of Cancer, Vol. 125, Núm. 8, pp. 1168-1176

2020

  1. Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal study

    BMC Psychology, Vol. 8, Núm. 1

  2. Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL)

    Lung Cancer, Vol. 150, pp. 62-69

  3. Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group

    Lung Cancer, Vol. 147, pp. 83-90

  4. Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control study

    Scientific Reports, Vol. 10, Núm. 1

  5. Serum phospholipids fatty acids and breast cancer risk by pathological subtype

    Nutrients, Vol. 12, Núm. 10, pp. 1-18

2019

  1. Feedforward regulation of Myc coordinates lineage-specific with housekeeping gene expression during B cell progenitor cell differentiation

    PLoS Biology, Vol. 17, Núm. 4

  2. Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study

    Breast Cancer Research and Treatment, Vol. 177, Núm. 1, pp. 115-125